FDA ApprovedUnited States
New Pill for a Rare Gene-Related Lung Cancer
Jideytro (zidesamtinib) — oral ROS1 kinase inhibitor after a prior ROS1 TKI
On 22 July 2026 the FDA labelled Jideytro (zidesamtinib) tablets for adults with locally advanced or metastatic ROS1-positive NSCLC who received a prior ROS1…
Jideytro is a US-labelled oral pill for adults whose ROS1-positive lung cancer has already been treated with another ROS1 kinase inhibitor.